Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Withdrawn 2Terminated 2Active not recruiting 2Unknown 1Recruiting 1Completed 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Breast 1

Conditions

Hematologic Neoplasms 1Fatigue 1Breast Neoplasms 1Breast Carcinoma In Situ 1

Interventions

Cyclophosphamide 166Docetaxel 154Bevacizumab 153Carboplatin 148Gemcitabine 146Cisplatin 146pembrolizumab 142Radiotherapy 135Paclitaxel 132Capecitabine 122Rituximab 115Oxaliplatin 104Fluorouracil 103Nivolumab 94Irinotecan 85Doxorubicin 85Pemetrexed 83Leucovorin 82Dexamethasone 82fludarabine 74fludarabine phosphate 72Bortezomib 69Etoposide 67Erlotinib Hydrochloride 66Cetuximab 65Methotrexate 58Trastuzumab 56Cytarabine 54Lenalidomide 50Everolimus 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Terminated × Infliximab × Clear all
NCT04438382 2026-05-15

Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis

Eastern Cooperative Oncology Group

Phase 2 Terminated
1 enrolled 1 chart
Other hematologic neoplasm

Hematologic Neoplasms

NCT00112749 2020-07-31

Infliximab in Treating Cancer-Related Fatigue in Postmenopausal Women Who Have Undergone Treatment for Breast Cancer

Jonsson Comprehensive Cancer Center

Phase 2 Terminated
7 enrolled
Breast

Breast Carcinoma In Situ, Breast Neoplasms, Fatigue

Data powered by HemOnc (CC BY 4.0) Colophon âš¡